Psychiatry CROs in Asia-Pacific
9 published
9 published CROs match Psychiatry in Asia-Pacific.
Locations in this set include United States, China, India, United Kingdom, Japan, and Australia.
Capabilities that show up most often in this set: Phase II Clinical Trials, Phase III Clinical Trials, Phase IV / Post-Marketing, Regulatory Affairs, and Clinical Operations.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
ClinilabsClinilabs is the leading CNS-focused CRO with 25+ years of expertise in neurotherapeutic clinical trials, offering Phase 1–4 trial management, early-phase development, clinical research units, and MedTech device expertise across psychiatry, neurology, substance use, and rare CNS disorders.
LinicalGlobal, award-winning CRO guiding clinical development from early-phase research to large-scale global studies with 90% client retention.
PPDPPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Signant HealthClinical trial technology and services provider with 30 years of experience supporting thousands of trials and 25% of novel drug approvals (FDA/EMA, 2021–2024). Offers eClinical solutions, protocol guidance from 50+ in-house scientists and clinicians, and global operational scale.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TFS HealthScienceGlobal mid-size CRO specializing in dermatology, internal medicine, neuroscience, oncology, and ophthalmology with Phase I-IV clinical development, real-world evidence studies, and flexible resourcing solutions across 600+ experts in Europe, North America, and Australia.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /indications/psychiatry/apac.md